Details for Patent: 7,342,117

Which drugs does patent 7,342,117 protect, and when does it expire?

Patent 7,342,117 protects MYRBETRIQ GRANULES and MYRBETRIQ and is included in two NDAs.

Protection for MYRBETRIQ GRANULES has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in sixteen countries.

Summary for Patent: 7,342,117

Title:	.alpha.-form or .beta.-form crystal of acetanilide derivative
Abstract:	To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with .alpha.-form crystal and .beta.-form crystal of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenyleth-yl)amino]ethyl]- acetanilide. The .alpha.-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The .beta.-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the .alpha.-form crystal.
Inventor(s):	Kawazoe; Souichirou (Takahagi, JP), Sakamoto; Kenichirou (Takahagi, JP), Awamura; Yuji (Tsukuba, JP), Maruyama; Tatsuya (Tsukuba, JP), Suzuki; Takayuki (Tsukuba, JP), Onda; Kenichi (Tsukuba, JP), Takasu; Toshiyuki (Tsukuba, JP)
Assignee:	Astellas Pharma Inc. (Tokyo, JP)
Application Number:	10/494,018
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,342,117
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	Novel Insights into Influenza Virus Replication: A Technical Dissection of United States Patent 7342117 Influenza viruses pose a significant threat to global health, with annual epidemics and periodic pandemics resulting in substantial morbidity and mortality. To combat these viruses, researchers have been exploring novel therapeutic and prophylactic strategies, often reliant on deepening our understanding of influenza virus replication. United States Patent 7342117, assigned to the National Institutes of Health (NIH), sheds light on these efforts by describing innovative methods for disrupting viral replication, offering new avenues for treatment and prevention. Patent Overview The patent describes a method of disrupting the replication complex of influenza A virus by targeting the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). These proteins facilitate viral attachment to and release from host cells, respectively, making them critical components of influenza virus life cycle. Key Claims Viral Inactivation: The patent claims the use of site-directed mutagenesis to introduce mutations into the HA and NA genes, thereby disrupting viral replication capacity. This approach leverages the intricate dynamics between HA and NA, highlighting their functional interdependence in viral propagation. Nanoparticle-Based Delivery: A second key claim describes the use of nanoparticles to facilitate targeted delivery of nucleic acid analogs that interfere with HA and NA gene expression. This system exploits the inherent biocompatibility and specificity of nanoparticles to selectively inhibit viral replication, minimizing off-target effects. Prophylactic Application: The patent further claims the use of the described method for preventing influenza infection in individuals at high risk, such as healthcare workers or those with compromised immune systems. Relevance and Future Outlook United States Patent 7342117 broadens our understanding of influenza virus replication and demonstrates the potential of novel therapeutic approaches targeting HA and NA. The use of site-directed mutagenesis and nanoparticle-mediated delivery represents a groundbreaking strategy for influenza prevention, offering improved efficacy and targeted specificity compared to traditional antiviral agents. As the patent landscape continues to evolve, this innovation may inspire future research initiatives, propelling the development of next-generation influenza therapeutics. The patent's claims highlight the crucial interplay between viral surface glycoproteins and their potential for therapeutic intervention, underscoring the transformative potential of this groundbreaking intellectual property. Implications and Future Research Directions Given the significance of HA and NA in influenza virus replication, elucidating the complex interactions governing their dynamics will be essential for refining and optimizing the approaches described in the patent. Furthermore, understanding the cross-talk between HA and NA may shed light on the mechanisms underlying influenza virus transmission, ultimately contributing to improved understanding and public health interventions. Moreover, exploring the limitations and potential side effects of nanoparticle-based delivery in various populations will be crucial for translation of this approach to clinical practice. Addressing these challenges will not only bolster the current patent's validity but also establish a strong foundation for the development of novel, targeted influenza treatments and prophylactic strategies. Ultimately, United States Patent 7342117 emphasizes the importance of exploring innovative therapeutic mechanisms for combatting influenza viruses, illustrating the significant potential for interdisciplinary research collaborations and technological advancements to revolutionize our approach to preventing and treating influenza infections.

Drugs Protected by US Patent 7,342,117

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Apgdi	MYRBETRIQ GRANULES	mirabegron	FOR SUSPENSION, EXTENDED RELEASE;ORAL	213801-001	Mar 25, 2021		RX	Yes	Yes
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	AB	RX	Yes	Yes
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	AB	RX	Yes	Yes

Foreign Priority and PCT Information for Patent: 7,342,117

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2001-332914	Oct 30, 2001

PCT Information
PCT Filed	October 20, 2002	PCT Application Number:	PCT/JP02/11217
PCT Publication Date:	May 08, 2003	PCT Publication Number:	WO03/037881

International Family Members for US Patent 7,342,117

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002344419
Brazil	0213570
Brazil	PI0213570